You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 14, 2024

CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Acetazolamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000115 ↗ Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed National Eye Institute (NEI) Phase 2 1990-12-01 To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed Ohio State University Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed National Center for Research Resources (NCRR) Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00108602 ↗ Sleep Apnea: Mechanism and Cerebrovascular Consequences Withdrawn US Department of Veterans Affairs N/A 2007-05-01 This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acetazolamide

Condition Name

Condition Name for Acetazolamide
Intervention Trials
Obstructive Sleep Apnea 12
Altitude Hypoxia 8
Chronic Obstructive Pulmonary Disease 8
Acute Mountain Sickness 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acetazolamide
Intervention Trials
Altitude Sickness 28
Sleep Apnea Syndromes 21
Sleep Apnea, Obstructive 16
Apnea 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acetazolamide

Trials by Country

Trials by Country for Acetazolamide
Location Trials
United States 123
Kyrgyzstan 18
Belgium 8
Israel 7
Switzerland 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acetazolamide
Location Trials
California 15
Massachusetts 11
Texas 7
Florida 6
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acetazolamide

Clinical Trial Phase

Clinical Trial Phase for Acetazolamide
Clinical Trial Phase Trials
Phase 4 50
Phase 3 14
Phase 2/Phase 3 7
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acetazolamide
Clinical Trial Phase Trials
Completed 64
Recruiting 26
Not yet recruiting 16
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acetazolamide

Sponsor Name

Sponsor Name for Acetazolamide
Sponsor Trials
University of Zurich 23
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov 16
University of California, San Diego 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acetazolamide
Sponsor Trials
Other 203
NIH 16
U.S. Fed 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.